EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions

Haider Altay, Ibrahim Al-Hashimi, Josh Matthews, Grace DeAlessandro, Ghanshyam H Ghelani iD

Vaccines · 01.06.2026 · 14 (6) · 497

DOI: 10.3390/vaccines14060497 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 01.06.2026. Verfasst von Haider Altay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic cancer vaccines are a promising immunotherapy approach in genitourinary (GU) cancers, designed to stimulate antitumor immune responses through antigen-specific T-cell activation. Although agents such as bacillus Calmette–Guérin in bladder cancer and sipuleucel-T in prostate cancer have shown success, vaccine monotherapy has generally produced limited clinical benefit due to tumor heterogeneity, poor immune infiltration, and immunosuppressive tumor microenvironments. Multiple vaccine platforms have demonstrated safety and immunogenicity in prostate, renal cell, and urothelial cancers, but efficacy remains modest. Current strategies focus on multi-antigen targeting, improved antigen presentation, and combination therapies with immune checkpoint inhibitors, radiotherapy, and targeted agents to enhance antitumor activity. Advances in personalized vaccine design and delivery systems are driving progress, though challenges such as manufacturing complexity, cost, and biomarker development remain. Ongoing translational and clinical research will be critical to improving the effectiveness of vaccine-based immunotherapy in GU malignancies.

Schlagwörter

Stichwörter der Autor:innen

cancer vaccinesgenitourinary cancersimmunotherapyneoantigensprostate cancerrenal cell carcinomatumor microenvironmenturothelial carcinoma

Autor:innen und Institutionen

  • Hematology and Medical Oncology, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA.

ORCID-Profile: Ghanshyam H Ghelani

Zitieren

APA

Altay, H., Al-Hashimi, I., Matthews, J., DeAlessandro, G., & Ghelani, G. H. (2026). Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions. Vaccines, 14(6), 497. https://doi.org/10.3390/vaccines14060497

Vancouver

Altay H, Al-Hashimi I, Matthews J, DeAlessandro G, Ghelani GH. Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions. Vaccines. 2026;14(6):497. doi:10.3390/vaccines14060497

BibTeX
@article{Altay2026,
  author = {Altay, Haider and Al-Hashimi, Ibrahim and Matthews, Josh and DeAlessandro, Grace and Ghelani, Ghanshyam H},
  title = {Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {497},
  doi = {10.3390/vaccines14060497}
}
Kostenlos starten →